Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis

NCT06449001 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06449001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06449001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 11, 2025
Completion date
March 10, 2028
Enrollment
6 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

extravascular hemolysis, paroxysmal nocturnal hemoglobinuria, pnh